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Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for
Extemporaneous Compounding
Abstract
Eslicarbazepine acetate is an anticonvulsant drug with a recent U.S. Food and Drug Administration
approval for expanded use in children and adolescents. Currently, eslicarbazepine acetate is only
available in the U.S. as 200-mg to 800-mg strength tablets (Aptiom), which are not easy to administer for
pediatric patients. This study was initiated to develop an oral suspension formulation for extemporaneous
compounding by pharmacists and to generate stability data for storage recommendations. Nine
suspension formulations of eslicarbazepine acetate were prepared from Aptiom tablets and
commercially available liquid vehicles using the standard mortar/pestle method. The vehicles varied
mainly in their solvents, viscosities, and sweeteners. The formulations were evaluated for ease of
preparation, physical properties, and initial potency. Two lead formulations were selected for a two-month
stability study at room temperature or under refrigeration (2°C to 8°C). The stability samples were
withdrawn at pre-determined time points and analyzed by visual inspection, pH measurement, and a
stability-indicating high-performance liquid chromatographic assay. The majority of the 9 formulations
were found to be easy to prepare and administer at a concentration of 40-mg/mL eslicarbazepine acetate.
Particle settling was observed in several formulations over time, but they were re-suspended satisfactorily
upon shaking. Two suspensions in 50:50 v/v mixtures of Ora-Sweet or Ora-Sweet SF with Ora-Plus were
selected as the lead formulations for the two-month stability study. At the initiation of the study, all
samples appeared as white and smooth suspensions with pH ranging from 4.39 to 4.46. The highperformance liquid chromatographic results confirmed that the initial samples contained 100.4% to
102.2% of the label claim strength. Over two months of storage at room temperature or refrigeration,
there were no significant changes in visual appearance, re-suspendability, pH, or potency for any samples.
No new degradation peaks were observed in any highperformance liquid chromatograms. Based on the
study results, two eslicarbazepine acetate suspensions are recommended for extemporaneous
compounding from Aptiom tablets. The formulations consist of 40 mg/mL eslicarbazepine acetate in
50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet SF:Ora-Plus. Once prepared, these suspensions can be stored
at room temperature or under refrigeration for up to two months.
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INTRODUCTION
Eslicarbazepine acetate (ESL) is an anti
convulsant drug indicated for the treatment
of partial-onset seizures.^ Recently, ESL has
received U.S. Food and Drug Administration
(FDA) approval for expanded use in chil
dren and adolescents 4 to 17 years of age.^
Currently, ESL is only available as 200-mg
to 800-mg strength tablets in the U.S. under
the brand name of Aptiom. With the pres
ence of excipients, the total weight of each
Aptiom tablet ranges from 235 mg to 933 mg
(Unofficial laboratory data generated by the
investigators using one lot of Aptiom tab
lets for each strength [n=10]). Swallowing
these large size tablets presents significant
challenges to many pediatric patients, and
elderly patients with dysphagia.®'^ An alter
native solution to overcome this barrier is to
prepare liquid suspensions from the tablet
dosage forms. The bioequivalence has been
established for ESL between the tablet and
suspension dosage forms at the 800-mg dose
level in healthy volunteers.® Another recent
publication also confirmed that the oral
bioavailability of ESL was similar between
the crushed tablets (taken with applesauce)
and intact tablets.®

www.IJPC.com

Eslicarbazepine acetate is an anticonvulsant drug with a recent U.S. Food and
Drug Administration approval for expanded use in children and adolescents.
Currently, eslicarbazepine acetate is only available in the U.S. as 200-mg to
800-mg strength tablets (Aptiom), which are not easy to administer for
pediatric patients. This study was initiated to develop an oral suspension
formulation for extemporaneous compounding by pharmacists and to
generate stability data for storage recommendations. Nine suspension
formulations of eslicarbazepine acetate were prepared from Aptiom tablets
and commercially available liquid vehicles using the standard mortar/pestle
method. The vehicles varied mainly in their solvents, viscosities, and
sweeteners. The formulations were evaluated for ease of preparation, physical
properties, and initial potency. Two lead formulations were selected for a twomonth stability study at room temperature or under refrigeration (2°C to 8°C).
The stability samples were withdrawn at pre-determined time points and
analyzed by visual inspection, pH measurement, and a stability-indicating
high-performance liquid chromatographic assay. The majority of the 9
formulations were found to be easy to prepare and administer at a
concentration of 40-mg/mL eslicarbazepine acetate. Particle settling was
observed in several formulations over time, but they were re-suspended
satisfactorily upon shaking. Two suspensions in 50:50 v/v mixtures of OraSweet or Ora-Sweet SF with Ora-Plus were selected as the lead formulations
for the two-month stability study. At the initiation of the study, all samples
appeared as white and smooth suspensions with pH ranging from 4.39 to 4.46.
The high-performance liquid chromatographic results confirmed that the
initial samples contained 100.4% to 102.2% of the label claim strength. Over
two months of storage at room temperature or refrigeration, there were no
significant changes in visual appearance, re-suspendability, pH, or potency for
any samples. No new degradation peaks were observed in any highperformance liquid chromatograms. Based on the study results, two
eslicarbazepine acetate suspensions are recommended for extemporaneous
compounding from Aptiom tablets. The formulations consist of 40 mg/mL
eslicarbazepine acetate in 50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet
SF:Ora-Plus. Once prepared, these suspensions can be stored at room
temperature or under refrigeration for up to two months.

The authors are affiliated with Wegmans School ofPharmacy, St. John Fisher College, Rochester,
New York.
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All retail and hospital pharmacists are
trained in extemporaneous compounding
and can prepare suspensions from imme
diate-release tablets, such as Aptiom tab
lets. A variety of oral suspension vehicles
are available commercially to facilitate the
preparation of oral suspensions, and they

include both sugar-based (SB) and sugarfree (SF) grades. Due to the relatively high
dose of ESL, formulation screening should
be carried out to optimize the palatability
and physical properties of the suspension
formulations. The first objective of this
study was to identify two oral suspension

RECOMMENDED FORMULA AND COMPOUNDING PROCEDURES FOR A 30-ML BATCH OF A
40-MG/ML ESLICARBAZEPINE ACETATE ORAL SUSPENSION
INGREDIENT

AMOUNT

Aptiom Tablet, 600 mg®

2 tablets

Suspension Vehicle*'

qs 30 mL

“Other strengths of Aptiom tablets may be used, and the number of tablets should be re-calculated accordingly
to provide the same total amount of esiicarbazepine acetate.
‘’The suspension vehicle is a mixture of 50:50 v/v Ora-Sweet:Ora-Plus or Ora-Sweet SF:Ora-Plus (from Perrigo
Pharmaceuticals). Include at least 20% overage to account for loss during transfer. For example, prepare at least
36 mL premix for the 30-mL batch of the suspension.
1.
2.

Calculate the required quantity of each ingredient for the total amount to be prepared.
Prepare the suspension vehicle by mixing 18 mL of Ora-Sweet (or Ora-Sweet SF) and 18 mL of Ora Plus.
Note: This includes 20% overage to account for loss during transfer.

3.

Pre-caiibrate a 2-oz amber plastic prescription bottle with purified water for 30 mL.

4.

Place the two Aptiom tablets in a 4-oz glass mortar.

5.

Crush the tablets and triturate thoroughly to a fine powder.

6.

Add 10 mL of suspension vehicle to the mortar in -2-mL increments and triturate until a smooth suspension

7.
8.

formulations (SB and SF) which are easy
to prepare by pharmacists, easy to dose,
palatable, and exhibit satisfactory physical
properties.
For nonsterile dosage forms prepared
by extemporaneous compounding, the
storage conditions and beyond-use dates
(BUD) are specified in the United States
Pharmacopeia? Without any stability data,
compounded suspensions in aqueous vehi
cles have to be stored under refrigeration
with a BUD of only 14 days. The ESL mole
cule has an ester functional group which is
prone to hydrolysis catalyzed by extreme
pH and heat. However, given the low-water
solubility of this drug,’^ the rate of hydroly
sis is expected to be slow for a suspension
formulation, especially when buffered pro
perly by the vehicle. The second objective of
this study was to conduct a stability evalua
tion on the selected oral suspensions with a
goal to extend the BUD for up two months at
both room temperature (RT) and under re
frigeration. This will provide flexibility for
the pharmacies to plan the compounding
activities and manage the inventory.

is obtained.

METHODS

Pour the mixture into the pre-calibrated bottle.

MATERIALS

Rinse the mortar and pestle with 5 mL of suspension vehicle and transfer into the bottle.
Note: Repeat this step once.

9.

Add a sufficient quantity of the suspension vehicle directly into the bottle to the pre-calibrated mark.

10.

Cap the bottle and shake thoroughly to disperse the suspension.

11.

Store the suspension at room temperature or under refrigeration for up to 2 months. Shake well before using.

TABLE 1. SOURCE INFORMATION OF SUSPENSION VEHICLES.

The pure active pharmaceutical ingre
dient (API) powder of ESL (Lot 1040155)
and 600-mg Aptiom tablets (Lot PNKN;
EXP June 2018) were provided by Sunovion
Pharmaceuticals Inc. (Marlborough,
Massachusetts). The suspension vehicles
were purchased from multiple
vendors as listed in Table 1.

VENDOR

CATALOG
NUMBER

NDC
NUMBER

LOT NUMBER AND
EXPIRATION DATE

Ora-Sweet

Perrigo

-

0574-0304-16

7260310, 6/30/2020

Ora-Sweet SF

Perrigo

-

0574-0302-16

5211709, 5/2019

Ora-Plus

Perrigo

::..v

0574-0303-16

7219887, 5/31/2019

Oral Mix

Medisca

-

38779-2512-8

137502/A, 10/2019

Oral Mix SF

Medisca

-

38779-2600-8

137485/A, 08/2018

VEHICLES

SyrSpend SF

Fagron

805359

51552-1123-5

16A05-U06-028553,1/5/2019

UniSpend anhydrous,

Fagron

906909

51552-1544-05

17K01-U05-040766 11/01/2019

Fagron

806910

51552-1545-05

17K01-U08-04074111/01/2019

; sweetened
UniSpend anhydrous,
unsweetened
NDC = National Drug Code: SF = sugar free
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INITIAL SCREENING
Prototype suspension for
mulations of 40-mg/mL ESL
were prepared at a 30-mL batch
size for initial screening. The
following procedures were used
to prepare each formulation. A
2-oz glass bottle was pre-cali
brated with 30 mL of purified
water. Two 600-mg Aptiom tab
lets were crushed and thorou
ghly triturated in a 4-oz glass
mortar. About 10 mL of vehicle
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was added to the mortar in -1-mL increments with trituration until
a smooth suspension was obtained. The suspension was carefully
poured into the pre-calibrated bottle, followed by two mortar rinses
of 5 mL of vehicle each. Finally, a sufficient amount of vehicle was
added directly into the bottle to the pre-calibrated mark. Each bottle
was shaken thoroughly to disperse the suspension. The ease of pre

TIBLE 2. PALATABILITY EVALUATION RUBRIC.

TASTE

SCALE OF 1 TO 5
(LEAST TO MOST INTENSE; 5 = MOST)

Bitter

1

2

3

4

5

Sweet

1

2

3

4

5

Sour

1

2

3

4

5

Salty

!■

2

3

4

5

Oily

1

2

3

4

5

Metallic

1

2

3

4

5

ODOR

SCALE OF 1 TO 5
(LEAST TO MOST INTENSE BAD
ODOR; 5 = MOST)
1

TEXTURE

2

12

1

(up to 10 minutes
after rinse)

4

5

3

4

5

SCALE OF 1 TO 5
(LEAST TO MOST IRRITATING/
AVERSIVE; 5 = MOST)

IRRITATION

AFTERTASTE

3

SCALE OF 1 TO 5 (LEAST TO MOST
GRITTY; 5 = MOST)

2

3

4

2

3

4

Two lead formulations of 40-mg/mL ESL in 50:50 v/v OraSweet:Ora-Plus or Ora-Sweet SF:Ora-Plus, were selected for the
two-month stability study. Batches of 120-mL suspensions were
prepared using the following method:
Method of Preparation of 120-mL Suspension Batches

1.

5

TABU 3. PROTOTYPE ORAL SUSPENSIONS OF 40 MG/ML
ESLICARBAZEPINE ACETATE.

FORMULATION
NUMBER

TWO-MONTH STABILITY STUDY

5

SCALE OF 1 TO 5 (LEAST TO MOST
AVERSIVE AFTERTASTE; 5 = MOST)
1

paration and initial observations were recorded immediately. The
suspensions were then evaluated for ease of dosing, palatability, and
physical properties.
The ease of dosing was first evaluated using the graduated oral
syringes (Catalog 2111; Total Pharmacy Supply, Inc., Arlington,
Texas). It was observed that some suspensions were difficult to
expel from the syringes. Therefore, the oral dosing spoons (Catalog
2102; Total Pharmacy Supply, Inc.) were added to the evaluation.
Palatability of the suspensions was evaluated by the two study
investigators using the rubric listed in Table 2. A teaspoonful dose
(5 mL) of each suspension was swished around in the mouth for
10 seconds and spat out. The mouth was rinsed with a sufficient
amount of warm water, and the palatability results were recorded
immediately. A minimum of a 2-hour-wait period was maintained
before the next sample. Evaluation of the physical properties of
the suspensions included particle settling, re-suspendability, and
foaming. One set of the suspensions were inspected and re-sus
pended daily for 4 days. A second set of the suspensions were left
undisturbed on a laboratory bench for 8 weeks, and camera images
were taken daily during the first week and weekly afterwards.
Re-suspendability of these suspensions was evaluated at the end of
the 8-week period.

Calculated the required quantity of each ingredient for the total
amount to be prepared.

2. Pre-calibrated a 4-oz amber prescription bottle with 120 mL of
purified water.
3. Crushed and thoroughly triturated eight 600-mg Aptiom tablets
in an 8-oz glass mortar.

VEHICLE

SUGAR-BASED
OR SUGAR-FREE

118-1

Ora-Sweet

Sugar-based

118-2

Ora-Sweet SF

Sugar-free

118-3

50:50 v/v Ora-Sweet:

Sugar-based

5. Poured the suspension carefully into the pre-calibrated bottle
followed by three mortar rinses of 20 mL of the vehicle each.

118-4

50:50 v/v Ora-Sweet SF:

Sugar-free

6. Added a sufficient amount of vehicle directly into the bottle, to
the pre-calibrated mark.

Ora-Plus

4. Added about 40 mL of the vehicle to the mortar in -lO-mL incre
ments with trituration until a smooth suspension was obtained.

7.

Ora-Plus

Shook the bottle thoroughly to disperse the suspension.

118-5

Oral Mix

Sugar-based

118-6

Oral Mix SF

Sugar-free

8. Transferred and packaged aliquots of the suspensions, 30 mL
each, in 2-oz amber prescription bottles for the stability study.
9. Stored the bottles at RT or under refrigeration (2°C to 8°C).

.118-7

SyrSpend SF

Sugar-free

118-8

UniSpend anhydrous

Sugar-based

sweetened
118-9

UniSpend anhydrous
unsweetened

www.IJPC.com

Sugar-free

Three replicates were included for each formulation. At 0,1-week,
2-week, 4-week, 6-week, and 9-week time points, the bottles were
shaken for re-suspension, and samples were withdrawn for visual

International Journal of Pharmaceutical Compounding
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TABLE 4. PROTOTYPE SUSPENSION FORMULATIONS AND INITIAL SCREENING RESULTS.

FORMULATION
NUMBER
118-1

il*

EASE OF
PREPARATION

EASE OF
DOSING

ACCEPTABLE
PALATABILITY

PARTICLE SETTLING
(AFTER 4 DAYS)

Yes

Yes

Yes

No

RESUSPENDABILITY

118-2

Yes

Yes

Yes

Yes

Yes

118-3

Yes

Yes

Yes

NO

Yes

118-4

Yes

Yes

Yes

No

Yes

118-5

Yes

Yes

Yes

No

Yes

118-6

Yes

Yes

Yes

No

Yes

118-7

No

Yes

Yes

No

Yes

118-8

Yes

No“

Yes

Yes

Yes

118-9

Yes

No"

No

Yes

Yes

-/

“It was easy to withdraw the suspension into the syringe, but it was very difficult to expel the suspension for dosing. There were no issues with dosing spoons.

TABLE 5. THE pH RESULTS OF THE TWO-MONTH STABILITY STUDY (/l=3).
pH
SAMPLE
40-mg/mL ESL suspension

STORAGE
TIME 0

1 WEEK

2 WEEKS

4 WEEKS

6 WEEKS

2°C to 8°C

4.45 ± 0.01

4.46 ± 0.01

4.48 ± 0.02

4.46 ± 0.02

4.51 ± 0.02

4.49

+ 0.02

RT

4.46 ± 0.01

4.46 ± 0.01

4.48 ± 0.03

4.45 ± 0.01

4.51 ± 0.01

4.48

± 0.01

4.42 ± 0.01

4.43

± 0.01

4.42

± 0.01

4.44

± 0.01

4.42

+ 0.01

± 0.02

4.42

± 0.01

4.43

± 0.01

4.43 ± 0.01

4.42

± 0.02

in 50:50 v/v
Ora-Sweet:Ora-Pius
40-mg/mL ESL suspension

2°C to S-C

in 50:50 v/v

4.39

+ 0.01

4.40 ± 0.01

RT

Ora-Sweet SF:Ora-Pius

4.44

9 WEEKS

ESL = esiicarbazepine acetate; RT = room temperature

TABLE 6. HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC RESULTS OF THE TWO-MONTH STABILITY STUDY (/l = 3).

% LABEL CLAIM
SAMPLE
40-mg/mL ESL suspension

STORAGE
TIME 0

1 WEEK

2 WEEKS

4 WEEKS

6 WEEKS

9 WEEKS

101.8 ± 1.4

102.1 ± 0.4

100.9 ± 0.1

102.7 ± 0.2

101.5 ± 0.4

102.3 ± 0.2

RT

102.2 +1.4

101.2 ± 0.3

102.5 ± 1.5

103.3 ± 1.1

102.4 ± 0.8

103.4 ± 0.6

2“C to 8”C

100.4 ± 0.3

100.8 ± 1.3

101.5 ± 2.1

101.3 ± 0.6

100.9 ± 0.9

101.0 ± 0.3

RT

101.9 ± 3.4

99.6 ± 0.3

101.3 ± 0.5

102.1 ± 0.7

102.0 ± 0.9

101.8 ±0.5

2°C to 8”C

in 50:50 v/v
Ora-Sweet:Ora-Pius
40-mg/mL ESL suspension
in 50:50 v/v
Ora-Sweet SF:Ora-Plus

ESL = esiicarbazepine acetate: RT = room temperature

inspection, pH measurement, and
high-performance liquid chroma
tographic (HPLC) analysis.
For the HPLC analysis, a
1.25-mL aliquot from each sta
bility sample was transferred
into a 50-mL volumetric flask
and diluted to the line with
50:50 v/v methanohwater. The
expected drug concentration
was 1 mg/mL. The flasks were
sonicated for 10 minutes and

436

allowed to cool to RT. About 1 mL of sample from each
flask was filtered through a 0.45-|im polytetrafluoroethylene membrane into an autosampler vial for the
HPLC analysis (see below for details). Please note that
it was not possible to transfer the desired 1.25-mL
volume accurately by the routine pipetting technique
for viscous suspensions. Instead, the samples were
transferred with weight monitoring. To be more specif
ic, each volumetric flask was tared on a balance, and
the sample was added slowly to the flask using a pipet
until the target weight was reached. The target weight
values were 1.44 g and 1.28 g for the Ora- Sweet/Ora-

International Journal of Pharmaceutical Compounding
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Plus and Ora-Sweet SF/Ora-Plus samples,
based on the measured density values of
1.155 g/mL and 1.023 g/mL, respectively.

HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHIC ANALYSIS
A stability-indicating HPLC method was
previously developed and implemented in
the investigators’ laboratory for ESL sus
pensions intended for enteral feeding tubes. 8
The method was verified to be suitable for

www.IJPC.com
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FIGURE IR. PHYSICAL APPEARANCE OF ESLICARBAZEPINE ACETATE SUSPENSION FORMULATIONS AFTER 0
TO 5 DAYS.
DAY

118-1

www.IJPC.com

118-2

118-3

118-4

118-5

118-6

118-7

118-8

118-9

the analysis of the current
oral suspension formula
tions. Briefly, the analysis
was performed using a
Shimadzu HPLC system
(Model LC-2010AHT) equipped with a Phenomenex
CIS column (Luna, 150 x
4.6 mm, 311, and 100 A). The
mobile phase consisted of
a methanol and water mix
ture (50:50 v/v) with 0.1%
trifluoroacetic acid. The
mobile phase flow rate was
set at 0.8 mL/minute, and
the column oven was set at
40°C. The sample injection
volume was 3 nL, and the
detection wavelength was
set at 230 nm. Under these
conditions, the retention
time of ESL was observed to
be about 8.9 minutes.
For calibration purposes,
standard solutions of
0.8 mg/mL, 0.9 mg/mL,
1.0 mg/mL, 1.1 mg/mL, and
1.2 mg/mL ESL were pre
pared from pure drug powder
in 50:50 v/v methanohwater. This range encom
passes 80% to 120% of the
expected drug concentra
tion in the diluted stability
samples for HPLC analysis.
A calibration curve was
constructed on each day of
the analysis by plotting the
peak area of ESL against
concentration. The curves
were found to be linear
over the concentration
range of the standards with
= 0.994 or better. The
middle standard was also
injected three times through
out the analysis on each
day to assess the method
precision. The intra-day
and inter-day coefficients
of variation were
within 0.6%.

International Journal of Pharmaceutical Compounding
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RESULTS AND
DISCUSSION
INITIAL SCREENING
Nine prototype suspension
formulations (118-1 to 118-9)
were prepared in commercially
available liquid vehicles as listed
in Table 3. Both sugar-based
(SB) and sugar-free (SF) systems
were included. The first seven
vehicle systems are commonly
used by pharmacists. The last
two are relatively new anhydrous
(lipid-based) vehicles, which
can potentially minimize the
hydrolytic degradation of drug
molecules, such as ESL. The
40-mg/mL drug concentration
was chosen so as to provide a
dose of200-mg ESL in a conven
ient 5-mL volume (equivalent to
a l-teaspoonful measurement in
the U.S.).
The initial screening data are
summarized in Table 4. All nine
formulations except 118-7 were
relatively easy to prepare from
the 600-mg strength Aptiom
tablets. The vehicle used in for
mulation 118-7, SyrSpend SF,
has a high intrinsic viscosity,
which led to a very thick drug
suspension and significant
drug loss during transfer steps.
The anhydrous (lipid-based)
formulations, 118-8 and 118-9,
exhibited a lower viscosity than
all other formulations (aque
ous based) and were easier
to transfer from mortar to
prescription bottles. In terms of
ease of dosing, aU suspensions,
except formulations 118-8 and
118-9, were compatible with oral
syringes and dosing spoons. The
palatabUity was also found to
be acceptable for most formu
lations whth an average score
of <3 (out a scale of 5) for each
evaluation category. Formulation
118-9 was scored 3.5 for its oily

taste and thus considered unacceptable. After 4 days
of storage at RT, some particle settling was observed in
formulations 118-2,118-8, and 118-9. The settling was
not unexpected, since the 118-2 contains no suspend
ing agents, and the two anhydrous vehicles have a low
intrinsic viscosity. Nevertheless, all formulations ex
hibited satisfactory re-suspendabUity upon shaking,
with no foaming issues.
A second set of the suspension formulations were
used to monitor the particle settling behavior over an
extended period of 8 weeks at RT without any phys
ical disturbances. The camera images from day 0 to
5 days eu'e shown in Figure lA, and the ones from 1
week to 8 weeks are shown in Figure IB. All suspen
sions retained their structure on days 0,1, and 2. On
Day-3, suspensions 118-8 and 118-9 exhibited signs
of particle settling along with the formation of a layer
of clear vehicle at the top surface. Suspensions 118-1
and 118-2 also showed initial signs of settling behavior.

International Journal of Pharmaceutical Compounding
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although a clear separation of vehicle and
the particles was not observed. The settling
behavior of these four suspensions pro
gressed over the following days and weeks.
Suspensions 118-5 and 118-6 started to
settle at the end of Week-1 and progressed
over the following weeks. Suspension 118-5
appeared to settle at a faster rate compared
to 118-6. Suspensions 118-3 and 118-4 began
settling during Week-2 and progressed over
the following weeks. Similar to the obser
vations above, suspension 118-3 appeared
to settle at a greater rate compared to 118-4.
Suspension 118-7 appeared to be most stable
against settling among all of the formula
tions evaluated. This formulation retained
its structure throughout the testing period.
The settling behavior of prepared suspen
sion formulations appeared to be a function

www.IJPC.com

of the intrinsic viscosity of the vehicles. Similar to previous observations, all formulations were re-suspended satisfactorily upon
shaking after 8 weeks of storage at RT.
Based on the initial screening data, formulations 118-3 and 118-4
were selected as the leads for additional evaluation. Formulation
118-3 contained 50:50 v/v Ora-Sweet:Ora-Plus (sugar based), and
formulation 118-4 contained 50:50 v/v Ora-Sweet SF:Ora-Plus
(sugar free). They provided the optimal balance of all the desired
attributes for compounded oral suspensions. HPLC analysis was
then performed on the freshly prepared samples of these two formulations. The ESL concentration was confirmed to match the
expected value, and there were no interfering peaks from the excipients used in the Aptiom tablets or the suspension vehicles.

TWO-MONTH STABILITY STUDY OF THE LEAD
FORMULATIONS
A two-month stability study was conducted on the two lead
suspension formulations stored at both RT and under refrigeration (2°C to 8°C) with three replicates for each condition. At the
initiation of the study, all samples appeared as white and smooth
suspensions. The pH readings of the samples ranged from 4.39 to
4.46 (Table 5), which were consistent with the pH range (4.0 to 4.5)
of the buffered source vehicles.® The HPLC results (Table 6) confirmed that the initial samples contained 100.4% to 102.2% of the
label claim strength of 40 mg/mL.
Over two months of storage, all stability samples exhibited good
re-suspendability. There were no significant changes in visual
appearance, pH (Table 5), or strength (Table 6) for any samples. The
HPLC chromatograms were also carefully examined for potential
degradation, and no new peaks were observed. The data suggest that
the two lead suspension formulations are stable physically and chemically at RT or under refrigeration for up to two months.
It is worth mentioning that the source vehicles in the two lead formulations contained an effective preservative system that consisted
of parabens and potassium sorbate.® Therefore, the ESL formulations are not expected to have issues of microbial growth over the
two-month storage period.
Based on the excipient information in the package insert^ and tablet weight data (Unofficial laboratory data generated by the invest!gators using one lot of Aptiom tablets for each strength [n=10]).
aU strength of Aptiom tablets are assumed to be prepared from
the same stock granulation or blend. In other words, all strengths
contain the same weight ratio of drug to excipients. Therefore, even
though the study was conducted using the 600-mg strength tablets.
all recommendations and findings from this study should be applicable when other strengths of Aptiom tablets are used to prepare
the oral suspensions.

“1

were selected from the initial screening work based on ease of preparation, ease of dosing, palatability, and physical properties. The
formulations consisted of 40 mg/mL of eslicarbazepine acetate in
50:50 v/v Ora-Sweet:Ora-Plus (sugar-based) or Ora-Sweet SF:OraPlus (sugar-free). Both formulations exhibited satisfactory physical
and chemical stability over the two months of storage period at RT
or under refrigeration (2°C to 8°C). The vehicles also contained preservatives to prevent potential microbial growth. The recommended
formula and compounding procedure for a 30-mL preparation is
conveniently provided on page 434.
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CONCLUSION
This study investigated oral suspension formulations of ESL
prepared by extemporaneous compounding. Two formulations
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